UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004701
Receipt number R000005596
Scientific Title A randomized phase II trial of adjuvant therapy with S-1 plus Hotyu-ekki-to (TJ41) versus S-1 alone for stage II/III gastric cancer
Date of disclosure of the study information 2011/02/01
Last modified on 2019/04/20 21:46:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized phase II trial of adjuvant therapy with S-1 plus Hotyu-ekki-to (TJ41) versus S-1 alone for stage II/III gastric cancer

Acronym

A randomized phase II trial of adjuvant therapy with S-1 plus Hotyu-ekki-to (TJ41) versus S-1 alone for stage II/III gastric cancer (KUGC07)

Scientific Title

A randomized phase II trial of adjuvant therapy with S-1 plus Hotyu-ekki-to (TJ41) versus S-1 alone for stage II/III gastric cancer

Scientific Title:Acronym

A randomized phase II trial of adjuvant therapy with S-1 plus Hotyu-ekki-to (TJ41) versus S-1 alone for stage II/III gastric cancer (KUGC07)

Region

Japan


Condition

Condition

Stage II or III gastric cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate alleviative effects of Hotyu-ekki-to on adjuvant chemotherapy with S-1 for stage II or III gastric cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

completion rate of one year adjuvant treatment with S-1

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

S-1:80mg/m2 PO bid (morning and evening) for 4 weeks with 2 weeks rest
For one year after surgery

Interventions/Control_2

S-1:80mg/m2 PO bid (morning and evening) for 4 weeks with 2 weeks rest,
Hotyu-ekki-to:7.5g/day (2.5gx3) PO everyday
For one year after surgery

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

(1)Histologically proven gastric cancer
(2) pStage II/III (except for T3N0 tumor) after R0 resection
(3) Patient with negative peritoneal washing cytology, and without liver metastasis
(4) Age 20-80 years old
(5) Patient who can start S-1 within 8 weeks after surgery.
(6)Adequate organ functions defined as indicated below
(i)WBC >= 3,000 /mm3 , WBC <= 12,000 /mm3
(ii)neutrophil >= 1,500 /mm3
(iii)hemoglobin >=9 g/dL
(iv)Plt >= 100,000 /mm3
(v) T.Bil <= 1.5 mg/dL
(vi) AST(GOT) , ALT(GPT) <= 100 IU/L
(vii) Ccr >= 60 mL/min
(7) Written informed consent

Key exclusion criteria

(1)Patient with active double cancer (synchronous double cancer and metachronous double cancer), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment.
(2)Patient who was diagnosed as cStage IV at any time during preoperative treatment
(3)Patient with administration contraindication of S-1
(4)Patient with regular use of H2-blocker, proton pump inhibitor, flucytosine, phenytoin, or warfarin.(5)Patients with past history of severe allergic reactions.
(6)Patient with severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, or uncontrollable diabetes mellitus, heart failure, renal failure, or liver cirrhosis
(7)Severe watery diarrhea.
(8)Pregnant or nursing patient or with intent to bear baby
(9) Men with partner willing to get pregnant
(10)Exclude patients who are recognized as inadequate patients by doctors with responsibility in this trial.

Target sample size

110


Research contact person

Name of lead principal investigator

1st name Yoshiharu
Middle name
Last name Sakai

Organization

Graduate School of Medicine, Kyoto University

Division name

Department of Surgery

Zip code

6068507

Address

54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JAPAN

TEL

075-366-7595

Email

ysakai@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name Hiroshi
Middle name
Last name Okabe

Organization

Graduate School of Medicine, Kyoto University

Division name

Department of Surgery

Zip code

6068507

Address

54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JAPAN

TEL

075-366-7595

Homepage URL


Email

hokabe@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Department of Surgery
Graduate School of Medicine, Kyoto University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto University Ethics comittiee

Address

54 Shogoin Kawaharacho, sakyo-ku, Kyoto

Tel

075-753-4680

Email

ethcom@kuhp.kyoto-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 02 Month 01 Day


Related information

URL releasing protocol

https://www.frontiersin.org/articles/10.3389/fonc.2019.00294/full?&utm_source=Email_to_authors_&utm_

Publication of results

Published


Result

URL related to results and publications

https://www.frontiersin.org/articles/10.3389/fonc.2019.00294/full?&utm_source=Email_to_authors_&utm_

Number of participants that the trial has enrolled

113

Results

Results: We randomly assigned 56 patients to group ST and 57 patients to group S.
The completion rates of S-1 were 54.5 and 50.9%, the median relative dose intensities
were 89.2 and 71.9%, and adverse events of grade 3 or 4 occurred in 45.5 and 54.5%
in groups ST and S, respectively. There was no significant difference in 3-year OS or RFS
between the two groups.

Results date posted

2019 Year 04 Month 20 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2019 Year 04 Month 17 Day

Baseline Characteristics

Characteristic S-1 plus TJ-41 S-1 only P*
(N = 55) (N = 55)
Sex 1.000
Male 37 (67.3) 37 (67.3)
Female 18 (32.7) 18 (32.7)
Age (median, range) 65, 49 to 76 64, 35 to 77 0.322
Neoadjuvant Chemotherapy 0.185
No 48 (87.3) 52 (94.5)
Yes 7 (12.7) 3 (5.5)
Type of Surgery 0.699
Distal/proximal gastrectomy 33 (60.0) 31 (58.4)
Total gastrectomy 22 (40.0) 24 (43.6)
T Category 0.088
T1 3 (5.5) 1 (1.8)
T2 9 (16.4) 16 (29.1)
T3 13 (23.6) 19 (34.5)
T4 30 (54.6) 19 (34.5)
N Category 0.281
N0 8 (14.5) 6 (10.9)
N1 13 (23.6) 19 (34.5)
N2 13 (23.6) 17 (30.9)
N3 21 (38.2) 13 (23.6)
Stage 0.561
II 21 (38.2) 24 (43.6)
III 34 (61.8) 31 (56.4)

Participant flow

We randomly assigned 56 patients to group ST and 57 patients to group S.

Adverse events

Adverse events of grade 3 or 4 occurred in 45.5 and 54.5% in TJ-41 and control group.

Outcome measures

The completion rates of S-1 were 54.5 and 50.9%,in TJ-41 and control group.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2010 Year 12 Month 07 Day

Date of IRB

2011 Year 01 Month 18 Day

Anticipated trial start date

2011 Year 03 Month 01 Day

Last follow-up date

2016 Year 07 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 12 Month 10 Day

Last modified on

2019 Year 04 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005596


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name